Cargando…

A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence

Due to differences in potency, efficacy, and affinity for CB1 receptors, similarities and differences in psychoactive effect profiles of natural cannabis and synthetic cannabinoids (SCs) cannot reliably be derived from equipotent dose comparisons. Instead, the current study proposes to compare the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theunissen, Eef Lien, Kuypers, Kim Paula Colette, Mason, Natasha Leigh, Ramaekers, Johannes Gerardus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160432/ https://www.ncbi.nlm.nih.gov/pubmed/35664482 http://dx.doi.org/10.3389/fpsyt.2022.891811

Ejemplares similares

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis
por: Theunissen, Eef L., et al.
Publicado: (2021)

Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders
por: Theunissen, Eef L., et al.
Publicado: (2019)

Cannabis Use and Neuroadaptation: A Call for Δ(9)-Tetrahydrocannabinol Challenge Studies
por: Ramaekers, Johannes G., et al.
Publicado: (2022)

A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
por: Prevete, Elisabeth, et al.
Publicado: (2021)

Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users
por: Ramaekers, Johannes G., et al.
Publicado: (2010)

Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review
por: Prevete, Elisabeth, et al.
Publicado: (2023)

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
por: Kiraga, Maggie Kamila, et al.
Publicado: (2022)

The Psychotomimetic Nature of Dreams: An Experimental Study
por: Mason, Oliver, et al.
Publicado: (2012)

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
por: Reckweg, Johannes T., et al.
Publicado: (2023)

Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
por: de Sousa Fernandes Perna, Elizabeth B., et al.
Publicado: (2018)

AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers
por: Morgan, C J A, et al.
Publicado: (2016)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Investigating Relationships Between Alcohol and Cannabis Use in an Online Survey of Cannabis Users: A Focus on Cannabinoid Content and Cannabis for Medical Purposes
por: Karoly, Hollis C., et al.
Publicado: (2020)

Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review
por: Eadie, Lauren, et al.
Publicado: (2021)

Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis
por: Mensen, Vincent T., et al.
Publicado: (2019)

Medicinal Cannabis and Synthetic Cannabinoid Use
por: Pichini, Simona, et al.
Publicado: (2020)

Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer’s Dementia: A Clinical Case Report
por: Defrancesco, Michaela, et al.
Publicado: (2020)

Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials
por: Vuilleumier, Caroline, et al.
Publicado: (2022)

Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia
por: Satodiya, Ritvij, et al.
Publicado: (2020)

Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’ and individually: a placebo-controlled trial
por: Hindocha, C., et al.
Publicado: (2017)

Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence
por: Bosker, Wendy M., et al.
Publicado: (2013)

Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective
por: van Ruitenbeek, Peter, et al.
Publicado: (2023)

Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users
por: Mason, Natasha L., et al.
Publicado: (2019)

Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users
por: Cohen, Koby, et al.
Publicado: (2020)

Synthetic cannabinoids use in a sample of opioid-use disorder patients
por: Alías-Ferri, María, et al.
Publicado: (2022)

Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions
por: Smith, Rosemary T., et al.
Publicado: (2023)

A continuum hypothesis of psychotomimetic rapid antidepressants
por: Haarsma, Joost, et al.
Publicado: (2021)

Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility
por: Cohen, Koby, et al.
Publicado: (2020)

Effects of synthetic cannabinoids on psychomotor, sensory and cognitive functions relevant for safe driving
por: Orazietti, Vasco, et al.
Publicado: (2022)

Cannabis and tolerance: acute drug impairment as a function of cannabis use history
por: Ramaekers, J. G., et al.
Publicado: (2016)

Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking
por: Smith, Robert C., et al.
Publicado: (2022)

Erratum: Cannabis and tolerance: acute drug impairment as a function of cannabis use history
por: Ramaekers, J. G., et al.
Publicado: (2016)

Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
por: Weinstein, Aviv M., et al.
Publicado: (2017)

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
por: Ramaekers, Johannes G, et al.
Publicado: (2020)

Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report
por: Awasthi, Harshal
Publicado: (2023)

Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication
por: Theunissen, Eef L., et al.
Publicado: (2011)

On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices
por: Tassone, Felicia, et al.
Publicado: (2023)

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials
por: Arkell, Thomas R., et al.
Publicado: (2021)

The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids—A Systematic Review
por: Cohen, Koby, et al.
Publicado: (2018)

Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists
por: Giorgetti, Arianna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u6ccnt1q8fqjj8fkiehi839mve